News and analysis on diagnostic technologies and applications.
The test will be used to identify which advanced or metastatic breast cancer patients with PIK3CA mutations are likely to respond to Novartis' alpelisib.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.
The CD Diagnostics lateral flow test detects human alpha defensins proteins in the synovial fluid of patients with a total joint replacement in about 10 minutes.
